Kymera Therapeutics Inc (NASDAQ: KYMR) on Friday, soared 3.38% from the previous trading day, before settling in for the closing price of $43.51. Within the past 52 weeks, KYMR’s price has moved between $18.89 and $53.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 241.22%. The company achieved an average annual earnings per share of -0.13%. With a float of $54.85 million, this company’s outstanding shares have now reached $55.59 million.
Let’s determine the extent of company efficiency that accounts for 187 employees. In terms of profitability, gross margin is 92.85%, operating margin of -223.0%, and the pretax margin is -191.26%.
Kymera Therapeutics Inc (KYMR) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kymera Therapeutics Inc is 15.30%, while institutional ownership is 93.73%. The most recent insider transaction that took place on Sep 17 ’24, was worth 651,766. In this transaction Director of this company sold 13,500 shares at a rate of $48.28, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 17 ’24, when Company’s Director proposed sale 13,500 for $48.48, making the entire transaction worth $654,480.
Kymera Therapeutics Inc (KYMR) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.25 earnings per share (EPS) for the period topping the consensus outlook (set at -0.38) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.79 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.90% during the next five years compared to -39.18% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Kymera Therapeutics Inc (KYMR) is currently performing well based on its current performance indicators. A quick ratio of 8.55 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 34.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -2.83 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Looking closely at Kymera Therapeutics Inc (NASDAQ: KYMR), its last 5-days average volume was 0.45 million, which is a drop from its year-to-date volume of 0.59 million. As of the previous 9 days, the stock’s Stochastic %D was 25.96%. Additionally, its Average True Range was 2.45.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 64.78%, which indicates a significant increase from 31.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.87% in the past 14 days, which was lower than the 65.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.96, while its 200-day Moving Average is $40.95. However, in the short run, Kymera Therapeutics Inc’s stock first resistance to watch stands at $46.19. Second resistance stands at $47.39. The third major resistance level sits at $48.85. If the price goes on to break the first support level at $43.53, it is likely to go to the next support level at $42.07. Now, if the price goes above the second support level, the third support stands at $40.87.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
Market capitalization of the company is 3.01 billion based on 64,765K outstanding shares. Right now, sales total 78,590 K and income totals -146,960 K. The company made 3,740 K in profit during its latest quarter, and -62,490 K in sales during its previous quarter.
